Expanded Access Program for Bezuclastinib and Sunitinib in GIST Patients
Cogent Biosciences is initiating an expanded access program for bezuclastinib to be used with sunitinib in GIST patients.
Therapeutic Area
Therapeutic area intelligence for GIST with 1 indexed intelligence signal across regulatory, clinical, competitive, and market developments.
No related entities indexed yet.
No catalysts indexed for this entity yet.
No related entities indexed yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.